McDonald’s shares took a hit this week after analysts painted a sobering picture of how weight-loss drugs might reshape the fast-food landscape. The stock dropped as much as 1.7% following a dramatic two-notch downgrade from Redburn Atlantic, which slashed its rating from buy to sell, according to CBS News. The culprit? Those appetite-suppressing medications everyone’s talking about.
Read the full article here
